<DOC>
	<DOCNO>NCT00418717</DOCNO>
	<brief_summary>The primary purpose study evaluate safety efficacy once-weekly dose etanercept rheumatoid arthritis . Currently , patient Japan use 25 mg etanercept two time week . If once-a-week regimen 50 mg approve , would convenient patient . This once-weekly regimen use country outside Japan .</brief_summary>
	<brief_title>Open Label , Dose-Regimen Study Evaluating Etanercept 50 mg Once-Weekly In Japanese Subjects With RA</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Main Subjects Japanese ancestry live Japan . Subjects receive approve dose 25 mg etanercept BIW least 6 month stable disease activity , determine investigator 's judgment 3 month test article administration . Subjects mildly active rheumatoid arthritis demonstrate 5 swollen joint 5 tender/painful joint . Main Prior treatment Disease Modifying AntiRheumatic Drugs ( DMARDs ) and/or methotrexate ( MTX ) within 6 month baseline visit . Subjects consider disease remission , per investigator 's judgment . Received biological drug , rituximab , antiCD4 agent , diphtheria interleukin2 fusion protein ( DABIL2 ) within 6 month prior baseline .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>